前收市價 | 2.8000 |
開市 | 2.8000 |
買盤 | 1.1000 |
賣出價 | 3.0000 |
拍板 | 12.50 |
到期日 | 2024-10-18 |
今日波幅 | 2.8000 - 2.8000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 310 |
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.